Natural Products and Bioprospecting最新文献

{"title":"Stingless bee propolis: a comprehensive review of chemical constituents and health efficacy","authors":"Nosiba A. Alsarayrah,&nbsp;Rafeezul Mohamed,&nbsp;Eshaifol A. Omar","doi":"10.1007/s13659-025-00545-4","DOIUrl":"10.1007/s13659-025-00545-4","url":null,"abstract":"<div><p>Propolis, consisting of plant-derived materials, wax, and bee secretions, is abundant in bioactive constituents like flavonoids, phenolic compounds, and terpenes, which enhance its various biological functions. These encompass antioxidant, anti-inflammatory, antibacterial, anticancer, antidiabetic, and immunomodulatory properties. Propolis has demonstrated effectiveness in the prevention and treatment of multiple illnesses, including cardiovascular disease, atherosclerosis, infections, diabetes, wound healing, and burns. Its extensive health benefits endorse its application in medications, nutritional supplements, and cosmetics, where it is acknowledged as a safe and efficacious natural product. Propolis, whether utilized in its raw state, as extracts, or in conjunction with other products, exhibits considerable promise in alternative medicine and nutritional health. Propolis extracts are crucial to examine as a key component in health and wellness, offering prospective applications in disease prevention and therapeutic support Further research is necessary to clarify its molecular mechanisms, examine potential allergic reactions, and determine ideal dosages for various ages. This article provides a comprehensive comparative examination of various propolis types, emphasizing their distinct phytochemical contents and varying biological effects concurrently. It integrates results from both in vitro and in vivo investigations, enhancing the comprehension of health applications and mechanisms of action, grounded comparisons in pertinent prior studies.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00545-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel polysaccharide in Polygonatum kingianum: structure elucidation, the activities of anti-inflammatory and the regulation of gut microbiota in vitro","authors":"Xiao Han,&nbsp;Xin-Xiu Ren,&nbsp;Dan-Yang Zhang,&nbsp;Qin-Feng Guo,&nbsp;Shi-Meng Li,&nbsp;Zhi-Long Xiu,&nbsp;Yue-Sheng Dong","doi":"10.1007/s13659-025-00542-7","DOIUrl":"10.1007/s13659-025-00542-7","url":null,"abstract":"<div><p>Polysaccharides are the primary active constituents of <i>Polygonatum kingianum</i> Coll. et Hemsl. However, the comprehensive characterization of <i>P</i>. <i>kingianum</i> polysaccharides (PKP) remains scarce, impeding investigations into the structure–activity relationship. In this study, a novel polysaccharide, PKP1, was purified using Cellulose DE-52 and Sephadex G-50 column chromatography, and its complete structure was elucidated through monosaccharide composition analysis, methylation analysis, as well as 1D and 2D NMR analysis. The results revealed that PKP1 primarily comprised Fru and Glc, exhibiting a molecular weight of 5.3 × 10³ Da and a polymer dispersity index of 1.20. The completed structure of PKP1 consisted of β-D-Fru<i>f</i>-(2 → , → 1,2)-β-D-Fru<i>f</i>-(6 → , → 1)-β-D-Fru<i>f</i>-(2 → and → 1)-α-D-Glc<i>p</i>-(6 → as the main chain sugar residues, with β-D-Fru<i>f</i>-(2 → and → 2)-β-D-Fru<i>f</i>-(6 → serving as the side chains sugar residues. The detailed structure of PKP1 suggested it is a novel Fru-dominated neutral polysaccharide. Biological assays indicated that PKP1 significantly reduced the levels of NO, IL-6, and TNF-α in RAW264.7 macrophages, while also exerting regulatory effects on the gut microbiota structure and its metabolites in vitro. Our findings enriched the understanding of the structural characteristics of <i>P</i>. <i>kingianum</i> polysaccharides and laid a solid foundation for considering <i>P</i>. <i>kingianum</i> as a potential functional food supplement.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00542-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: New acetogenin katsuurallene from Laurencia saitoi collected from Katsuura, Japan","authors":"Yu Minamida,&nbsp;Hiroshi Matsuura,&nbsp;Takahiro Ishii,&nbsp;Miyu Miyagi,&nbsp;Yuto Shinjo,&nbsp;Kosuke Sato,&nbsp;Takashi Kamada,&nbsp;Yoshihiro Mihara,&nbsp;Iwao Togashi,&nbsp;Keisuke Sugimoto,&nbsp;Tsuyoshi Abe,&nbsp;Norio Kikuchi,&nbsp;Minoru Suzuki","doi":"10.1007/s13659-025-00538-3","DOIUrl":"10.1007/s13659-025-00538-3","url":null,"abstract":"","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00538-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144914564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"(+)-/(−)-Ormohenins A and B, two pairs of ormosanine-type enantiomers and their derivatives with neuroprotective activity from Ormosia henryi Prain","authors":"Ming Cheng,&nbsp;Xian-Si Zeng,&nbsp;Zhao-Yun Yin,&nbsp;Xiao-Yan Xie,&nbsp;Jia-Wen Zhu,&nbsp;Jian-Feng Wang,&nbsp;Ying-Kun Sheng,&nbsp;Jin-Biao Xu","doi":"10.1007/s13659-025-00539-2","DOIUrl":"10.1007/s13659-025-00539-2","url":null,"abstract":"<div><p>Two pairs of undescribed alkaloid enantiomers, (+)-/(−)-ormohenins A (<b>1</b>) and B (<b>2</b>), were isolated from the seeds of <i>Ormosia henryi</i> Prain, along with four undescribed alkaloids (<b>3</b>, <b>4</b>,<b> 7</b> and <b>8</b>) and seven known ones (<b>5</b>, <b>6</b>, <b>9</b>–<b>13</b>). Compounds <b>1</b>–<b>6</b> belong to the ormosanine-type alkaloids, compounds <b>7</b>, <b>9</b>, and <b>11</b> are of the lupinine-type, compounds <b>8</b> and <b>10</b> are classified as anagyrine-type alkaloids, <b>12</b> and <b>13</b> are cytisine-type alkaloids. The chemical structures of <b>1</b>–<b>13</b> were elucidated through comprehensive NMR and MS data analyses. Furthermore, the racemates (±)-<b>1</b> and (±)-<b>2</b> were successfully resolved into their respective optically pure enantiomers using a chiral HPLC system. The absolute configurations of compounds <b>1–3</b> were determined using single-crystal X-ray diffraction and corroborated by DFT calculations of specific rotations. The absolute configurations of <b>4</b>, <b>7</b>, and <b>8</b> were assigned by the experimental electronic circular dichroism (ECD) with those predicted using TDDFT calculations. Compound <b>12</b> exhibited significant acetylcholinesterase (AChE) inhibitory activity with the IC₅₀ value of 6.581 ± 1.203 μM. The neuroprotective effects of these compounds against A<i>β</i>_25-35 induced cell damage in PC12 cells were investigated, and compounds<b> 3</b>, <b>9</b>, and <b>12</b> exhibited significant neuroprotective effects against A<i>β</i>_25-35 induced PC12 cell damage, with the EC₅₀ values of 7.99–15.49 μM, respectively.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00539-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144893931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual inhibition of FAS and HAS2/3 by 4-MU in Realgar-Coptis chinensis unveils a metabolic checkpoint for liver cancer therapy","authors":"Songtao Wu,&nbsp;Yingying Wang,&nbsp;Denghui Deng,&nbsp;Guohua Zheng,&nbsp;Hanxiang Mei,&nbsp;Cong Wang,&nbsp;Xiang Zheng,&nbsp;Chun Gui,&nbsp;Fei Liao,&nbsp;Meixian Xiang","doi":"10.1007/s13659-025-00540-9","DOIUrl":"10.1007/s13659-025-00540-9","url":null,"abstract":"<div><p>Modern pharmacology has found that both Realgar and <i>Coptis chinensis</i> can induce apoptosis in tumor cells, and traditional Chinese medicine theory suggests the possibility of combining the two, however, the specific mechanisms involved have not been elucidated. This study investigated the therapeutic mechanism of the Realgar-Coptis chinensis drug pair (RCCD) against hepatocellular carcinoma (HCC) by identifying its key active compounds and targets. Through integrated LC–MS analysis, transcriptomics, network pharmacology, and bioinformatics, we identified the mechanism of action, key bioactive compounds, and core targets. Molecular docking, molecular dynamics simulations, and microscale thermophoresis (MST) validated the binding affinity between key compounds and core targets. TIMER2.0 database was used to analyze the relationship between the core targets and HCC. H22 tumor xenograft mouse model and immunohistochemistry and pathology analyses were performed to validate the antitumor efficacy of the active compounds. RCCD has a high degree of selectivity of lipid metabolism pathway, 4-Methylumbelliferone (4-MU) was the key active compound with strong binding activity to the core target fatty acid synthase (FAS), and 4-MU down-regulated the expression of FASN in tumor tissues and induced apoptosis in HCC cells. In addition, as a hyaluronan synthase (HAS2/3) inhibitor, 4-MU interfered with the HA-dependent tumor microenvironment and fibrosis process by inhibiting HAS2/3. Thus, 4-MU may inhibit tumor progression by inhibiting FAS and HAS2/3. 4-MU extracted from RCCD exerts anti-HCC effects by modulating the activities of FAS and HAS2/3, thereby reprogramming lipid metabolism and regulating hyaluronan synthesis.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00540-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144880798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Senkyunolide H reverses depression-induced breast cancer progression by regulating CXCR2","authors":"Yingchao Wu,&nbsp;Jiaqi Cui,&nbsp;Liushan Chen,&nbsp;Jieting Chen,&nbsp;Junfeng Huang,&nbsp;Congwen Yang,&nbsp;Yuqi Liang,&nbsp;Qianjun Chen,&nbsp;Qian Zuo","doi":"10.1007/s13659-025-00543-6","DOIUrl":"10.1007/s13659-025-00543-6","url":null,"abstract":"<div><h3>Background</h3><p>Depression promotes breast cancer progression. Given the lack of specific targets for depression-associated breast cancer, there are currently no therapeutic drugs for this type of breast cancer.</p><h3>Methods</h3><p>Transcriptomic analysis was conducted to identify and functionally annotate genes with differential expression in breast cancer patients exhibiting depressive symptoms. Subsequently, Mendelian randomization was employed to investigate the causal associations between these pivotal genes and breast cancer, thereby validating their potential roles as therapeutic targets. Furthermore, molecular docking techniques were utilized to screen for candidate compounds that may exert therapeutic effects on depression-associated breast cancer. The efficacy of the selected compounds was further assessed using both in vitro cellular experiments and in vivo animal models.</p><h3>Results</h3><p>We identified IL-8 as a key gene involved in depression-mediated breast cancer progression using transcriptomics. Mendelian randomized analysis suggested that high IL-8 expression promoted breast cancer progression. Further studies demonstrated that IL-8 mediated the breast cancer-promoting effect of depression through the receptor CXCR2. Evidence from both in vitro and in vivo experiments indicates that senkyunolide H may exert its therapeutic effect by regulating CXCR2, thereby counteracting the protumor effects associated with depression in breast cancer.</p><h3>Conclusion</h3><p>Depression activates CXCR2-mediated breast cancer cell proliferation through IL-8, and senkyunolide H regulates CXCR2 and inhibits its ability to block the cancer-promoting effects of depression, ultimately inhibiting the growth of breast cancer in the context of depression.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00543-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144880797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Design of 20‑deoxyingenol‑esters‑based PKC agonists and their lysosome biogenesis‑enhancing activity","authors":"Jia‑Jia Wan,&nbsp;Qiu‑Yuan Yin,&nbsp;Mao Sun,&nbsp;Cui‑Shan Zhang,&nbsp;Hao‑Jing Zang,&nbsp;Pei‑Tong Yao,&nbsp;Ming‑Rui Yuan,&nbsp;Ding‑Kang Chen,&nbsp;Feng Guo,&nbsp;Qun Chen,&nbsp;Bo‑Wen Ouyang,&nbsp;Zi‑Fei Xu,&nbsp;Ming‑Ming Cao,&nbsp;Chong‑Lin Yang,&nbsp;Xiao‑Jiang Hao,&nbsp;Ying‑Tong Di","doi":"10.1007/s13659-025-00537-4","DOIUrl":"10.1007/s13659-025-00537-4","url":null,"abstract":"","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00537-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144868886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Concise syntheses of natural diarylheptanoids containing a 1,4‑pentadiene unit","authors":"Guang Tao,&nbsp;Xin‑Yue Hu,&nbsp;Hong‑Xing Liu,&nbsp;Xing‑Ren Li,&nbsp;Li‑Dong Shao,&nbsp;Gang Xu","doi":"10.1007/s13659-025-00525-8","DOIUrl":"10.1007/s13659-025-00525-8","url":null,"abstract":"","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00525-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144861494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Xiaoyankangjun tablet alleviates dextran sulfate sodium‑induced colitis in mice by regulating gut microbiota and JAK2/STAT3 pathway","authors":"Suqin Yang,&nbsp;Jingtao Huang,&nbsp;Wenjing Tan,&nbsp;Xiankun Xia,&nbsp;Dali Gan,&nbsp;Yalei Ren,&nbsp;Hanwen Su,&nbsp;Meixian Xiang","doi":"10.1007/s13659-025-00536-5","DOIUrl":"10.1007/s13659-025-00536-5","url":null,"abstract":"","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00536-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144832220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks","authors":"Luana Layse Câmara de Almeida,&nbsp;Sayoane Pessoa Fernandes,&nbsp;Genil Dantas de Oliveira,&nbsp;Marcelly da Silveira Silva,&nbsp;Thalisson Amorim de Souza,&nbsp;Valnês S. Rodrigues-Junior,&nbsp;Samuel Paulo Cibulski","doi":"10.1007/s13659-025-00533-8","DOIUrl":"10.1007/s13659-025-00533-8","url":null,"abstract":"<div><p>Tuberculosis (TB) is a leading infectious disease killer and one of the major causes of deaths worldwide. Although TB is a curable and preventable disease, in 2023, approximately 10.8 million people fell ill with TB and there were an estimated 1.25 million of deaths worldwide. Despite some research progress for new drug candidates, drug repurposing, and new regimens, there is still an urgent need for the new medicins to treat TB, especially due to the growing cases of multidrug and extensively drug-resistant (MDR/XDR) strains. Drug resistance is a challenging obstacle to TB care and prevention globally, making TB harder and longer to treat, often with poorer outcomes for patients. The Actinomycetota encompass Gram-positive bacteria that produce a milieu of bioactive metabolites, including antibiotics, antiproliferative drugs, immunosuppressive agents, and other important medical molecules. Actinomycetota have a special place in the therapeutic arsenal to fight TB, as rifamycins, aminoglycosides, and cycloserine are derived from <i>Streptomyces</i> species, one of the most important genera in this phylum. Furthermore, hundreds of antimycobacterial metabolites have been isolated from Actinomycetota and can serve as effective drugs or useful agents for the discovery of new lead compounds to combat TB. The present review covers more than 171 isolated substances as potential antimycobacterial agents discovered between the years 1972 to 2024. Among the most potent compounds, with MIC in the submicromolar range, steffimycins, ilamycins/rufomycins, nosiheptide, actinomycins, lassomycin and boromycin are the most promising compounds. These compounds represent highly promising candidates for development of new antitubercular drugs. Additionally, some of these substances also demonstrated activity against resistant <i>Mycobacterium tuberculosis</i> (Mtb) strains, which is particularly relevant given the difficulty of treating MDR and XDR strains. Thus, actinobacteria have played and continue to play an important role in fight TB, remaining a promising source of antibiotic metabolites. Their unique metabolic diversity enables the production of metabolites with innovative mechanisms of action, making them a strategic reservoir for discovering therapies against untreatable forms of the disease.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"15 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s13659-025-00533-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144810776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}